The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

The FDA is forcing Pfizer and Moderna to expand warning labels about the risks of two forms of heart damage, myocarditis and ...

Key Takeaways Federal regulators have issued a warning about rare heart inflammation in young males after mRNA COVID ...

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...

Moderna will merge its technology and HR teams departments, thanks to their increasing reliance on AI and ongoing OpenAI ...

Moderna’s Chief People & Digital Officer, Tracey Franklin, has become the latest high-profile executive to reveal how agentic ...

Moderna, Inc. (NASDAQ:MRNA) shares soared to the top of the S&P 500 gainers in early afternoon trading on May 20, surging by ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1389.55 with a total volume of ...

Moderna, Inc. (NASDAQ:MRNA) made a name for itself by quickly developing an effective coronavirus vaccine when the world needed it the most. However, the stock has largely struggled since the pandemic ...

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu shot for people 50 and over, a setback for the company. The biotech ...